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Abstract
Baekground: One of the most important limiting efficacy of monoclonal antibodies (mAb) is
their immunogenicity that may influence the diagnostic and therapeutic process of them. The aim
of this study was determine the presence of antibody against some mAb including Rituximab,
Bevacizumab and Trastuzumab in malignant patients.
Methods: Blood samples were collected from 32 patients with lymphoma and leukemia, 43
patients with breast cancer and 23 patients with adenocarcinoma before and after treatment with
Rituximab, Trastuzumab and Bevacintmab, respectively. The serum levels of human antibodies
against mentioned mAbwere determined by designing a standard of sandwich ELISA method.
Results: The presence of human antibodies against mentioned antibodies was detecte d in 4 of 32
(12.5%) of Rituximab-treated patients and 7 of 43 (16.3%) of Trastuzumab- treated patients with
mean titer of 2.33+0.37 AU/nL and 1.2+0.21 AU/mL, respectively. none of Bevacizumab-
treated patients was developed antibody against administrated mAb.
Conclusion: The production of antibody against therapeutic mAb Rituximab and
Trastuzumabwas detected in a number of treated patients that may influence their efficacy.
Bevacizumab did not show immunogenicity in our treated patients.
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